| 1. |
Masutani K, Fujisaki A, Yamada S, Noguchi H, Okabe Y, Kitada H, Sugitani A, Katafuchi R, Tsuruya k, Tanaka M, Iida M, Detection of anti-HLA antibody by flow-cytometric panel recipient with frequent episodes of acute rejection., Clinical Transplantation, 22(19):36-41, 2008.04. |
| 2. |
Okabe Y, Kitada H, Miura Y, Nishiki T, Kurihara K, Kawanami S, Terasaka S, Kaku K, Noguchi H, Sugitani A, Tanaka M, Pancreas transplantation: a single-institution experience in Japan, Surg Today, 43(12):1406-1411, 2013.04, PURPOSE:
We herein report our experience with pancreas transplantation in 26 patients at a single institution in Japan between August 2001 and December 2011.
METHODS:
We reviewed the medical records of 26 pancreas transplantations performed in our institute.
RESULTS:
The early complications (within 2 weeks) included one graft venous thrombosis, one arterial thrombosis, and two reoperations for bleeding. Of the 26 pancreas transplant recipients, five lost pancreas graft function. Of 24 simultaneous pancreas-kidney recipients, three lost kidney graft function due to noncompliance. The patient, pancreas, and kidney survival rates were 100, 96 and 93 % at 1 year; 100, 80 and 93 % at 5 years; and 100, 67 and 68 % at 10 years, respectively. Of all these complications, venous thrombosis after pancreas transplantation was the most critical.
CONCLUSIONS:
As the largest series of pancreas transplantations in a single institution in Japan, our series yielded better results than the worldwide data recorded by the International Pancreas Transplant Registry. Routine postoperative anticoagulation therapy is not necessary for the prevention of graft thrombosis if sufficient fluid infusion is strictly controlled and the graft blood flow is frequently monitored. When graft thrombosis occurs, both early detection and appropriate intervention are extremely important if the pancreas graft is to survive.
. |
| 3. |
Noguchi H, Nakagawa K, Ueki K, Tsuchimoto A, Kaku K, Okabe Y, Nakamura M, Response to Treatment for Chronic-active T Cell-mediated Rejection in Kidney Transplantation: A Report of 3 Cases, Transplant Direct, 10.1097/TXD.0000000000001079
, 6(12):e628, 2020.04. |
| 4. |
Tsuchimoto A, Masutani K, Omoto K, Okumi M, Okabe Y, Nishiki T, Ota M, Nakano T, Tsuruya K, Kitazono T, Nakamura M, Ishida H, Tanabe K, Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review, Clin Exp Nephrol, 10.1007/s10157-018-1672-1 , 23(4):561-568, 2018.04, Abstract
BACKGROUND:
The safety of kidney transplantation (KT) for end-stage kidney disease (ESKD) after haematopoietic stem cell transplantation (HSCT) for haematological disease has not been investigated thoroughly.
METHODS:
In this retrospective multicentre study, we investigated the clinical courses of six ESKD patients that received KT after HSCT for various haematological diseases. Data for six such patients were obtained from three institutions in our consortium.
RESULTS:
Two patients with chronic myeloid leukaemia, one with refractory aplastic anaemia and another one with acute lymphocytic leukaemia received bone marrow transplantation. One patients with acute lymphocytic leukaemia received umbilical cord blood transplantation, and one with mantle cell lymphoma received peripheral blood stem cell transplantation. The patients developed ESKD at a median of 133 months after HSCT. Two patients who received KT and HSCT from the same donor were temporarily treated with immunosuppressive drugs. The other patients received KT and HSCT from different donors and were treated with antibody induction using our standard regimens. For one patient with ABO-incompatible transplantation, we added rituximab, splenectomy, and plasmapheresis. In the observational period at a median of 51 months after KT, only one patient experienced acute T-cell-mediated rejection. Four patients underwent hospitalization because of infection and fully recovered. No patient experienced recurrence of their original haematological disease. All patients survived throughout the observational periods, and graft functions were preserved.
CONCLUSIONS:
Despite the high infection frequency, survival rates and graft functions were extremely good in patients compared with previous studies. Therefore, current management contributed to favourable outcomes of these patients
. |
